Edition:
United States

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

28.15USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$28.15
Open
$28.20
Day's High
$28.40
Day's Low
$27.95
Volume
40,378
Avg. Vol
88,086
52-wk High
$35.95
52-wk Low
$16.30

Latest Key Developments (Source: Significant Developments)

Regenxbio reports third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - ‍cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016​.  Full Article

RTW Investments reports 5 pct passive stake in Regenxbio
Thursday, 5 Oct 2017 05:34pm EDT 

Oct 5 (Reuters) - RTW Investments:RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing.  Full Article

Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 mln-SEC filing
Tuesday, 3 Oct 2017 08:59am EDT 

Oct 3 (Reuters) - Dimension Therapeutics Inc ::Dimension Therapeutics says on termination of merger with Ultragenyx co will be required to pay Ultragenyx a termination fee of $2.9 million-SEC filing.Dimension Therapeutics-co to reimburse Ultragenyx for $2.9 million fee paid by Ultragenyx on behalf of dimension for termination of Regenxbio deal.  Full Article

Ultragenyx Pharmaceutical comments on Dimension Therapeutics' announcement
Monday, 2 Oct 2017 09:22am EDT 

Oct 2 (Reuters) - Ultragenyx Pharmaceutical: :Ultragenyx Pharmaceutical comments on dimension therapeutics' announcement that co's offer is a "superior proposal" in its merger agreement with regenxbio.Ultragenyx Pharmaceutical says is "pleased" that dimension board determined that all-cash offer to buy dimension for $6.00 per share is a superior proposal.  Full Article

Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD
Wednesday, 20 Sep 2017 07:00am EDT 

Sept 20 (Reuters) - Regenxbio Inc ::Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD.Regenxbio Inc - ‍ plans to share an interim trial update for Phase I clinical trial of RGX-314 by end of 2017​.  Full Article

Dimension Therapeutics to pay $2.9 mln to Regenxbio incase merger terminates
Friday, 25 Aug 2017 08:37am EDT 

Aug 25 (Reuters) - Dimension Therapeutics Inc :Dimension Therapeutics - Upon termination of merger ,under specified circumstances, co required to pay Regenxbio termination fee $2.9 million- SEC filing.  Full Article

Regenxbio to acquire Dimension Therapeutics
Friday, 25 Aug 2017 08:00am EDT 

Aug 25 (Reuters) - Dimension Therapeutics Inc :Regenxbio to acquire Dimension Therapeutics.Dimension Therapeutics inc - deal for ‍$3.41 per share​.Dimension Therapeutics Inc says ‍boards of directors of both companies have unanimously approved transaction​.Dimension shareholders will receive 0.1573 shares of Regenxbio in exchange for each of their shares in Dimension.Dimension Therapeutics Inc - ‍ind application is anticipated to be filed for DTX201 in early 2018​.Dimension Therapeutics Inc - ‍Regenxbio will acquire DTX201 for treatment of hemophilia A. DTX201​.Dimension shareholders are expected to own approximately 10.9% percent of combined entity.Dimension Therapeutics - co will, following consummation of acquisition, become a wholly owned subsidiary of Regenxbio​.  Full Article

Avexis and Regenxbio announce new exclusive worldwide licenses
Wednesday, 7 Jun 2017 04:00pm EDT 

June 7 (Reuters) - Avexis Inc : :Avexis and Regenxbio announce new exclusive worldwide licenses for the treatment of two rare neurological monogenic disorders using NAV AAV9 vector.Avexis - ‍Regenxbio to receive upfront payment upon execution, ongoing fees, milestone payments & royalties on net sales of products incorporating NAV AAV9 vector​.Avexis Inc- intends to move forward with initiating ind-enabling studies in both RTT and ALS, plans to provide details on programs in 2h 2017.  Full Article

Regenxbio reports Q1 revenue $500,000
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Regenxbio Inc :Regenxbio reports first quarter 2017 financial results and recent operational highlights.Q1 loss per share $0.82.Q1 revenue $500,000 versus $400,000.Q1 revenue view $1.4 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.76 -- Thomson Reuters I/B/E/S.Regenxbio -On track to initiate dosing of patients in RGX-314 Phase I trial for wet AMD by mid-2017, continuing enrollment of patients in RGX-501 Phase I/II trial for HOFH.Regenxbio Inc says interim trial updates for RGX-314 and RGX-501 anticipated by year-end 2017.Regenxbio Inc says revenues were $0.5 million for three months ended March 31, 2017, compared to $0.4 million for three months ended March 31, 2016.Q1 earnings per share view $-0.76, revenue view $1.4 million -- Thomson Reuters I/B/E/S.  Full Article

Regenxbio prices offering of 3.70 mln shares at $20.50/share
Tuesday, 21 Mar 2017 09:31pm EDT 

Regenxbio Inc : Regenxbio announces pricing of public offering of common stock .Says public offering of 3.70 million common shares priced at $20.50per share.  Full Article

BRIEF-Regenxbio reports third quarter financial results

* Regenxbio reports third quarter 2017 financial results and recent operational highlights